$483 Million is the total value of Octagon Capital Advisors LP's 34 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 35.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $79,396,000 | +237.4% | 1,256,265 | +129.1% | 16.44% | +85.5% |
| IMAB | Buy | I MABsponsored ads | $79,178,000 | +208.2% | 943,156 | +77.9% | 16.40% | +69.4% |
| CRIS | Buy | CURIS INC | $28,912,000 | +20.0% | 3,582,629 | +68.3% | 5.99% | -34.0% |
| BBIO | New | BRIDGEBIO PHARMA INC | $23,221,000 | – | 380,928 | +100.0% | 4.81% | – |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $20,874,000 | +85.8% | 760,164 | +90.0% | 4.32% | +2.2% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS IN | $20,017,000 | +22.0% | 831,267 | +119.7% | 4.15% | -32.9% |
| ZLAB | New | ZAI LAB LTDadr | $19,351,000 | – | 109,335 | +100.0% | 4.01% | – |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $18,773,000 | +62.3% | 561,398 | 0.0% | 3.89% | -10.7% | |
| VERA | New | VERA THERAPEUTICS INCcl a | $15,008,000 | – | 1,132,671 | +100.0% | 3.11% | – |
| XLRN | ACCELERON PHARMA INC | $14,100,000 | -7.5% | 112,363 | 0.0% | 2.92% | -49.1% | |
| ARVN | ARVINAS INC | $13,745,000 | +16.5% | 178,500 | 0.0% | 2.85% | -35.9% | |
| DYN | DYNE THERAPEUTICS INC | $12,280,000 | +35.5% | 583,649 | 0.0% | 2.54% | -25.5% | |
| IPSC | New | CENTURY THERAPEUTICS INC | $11,839,000 | – | 403,523 | +100.0% | 2.45% | – |
| GOSS | GOSSAMER BIO INC | $11,475,000 | -12.2% | 1,413,138 | 0.0% | 2.38% | -51.7% | |
| RNA | AVIDITY BIOSCIENCES INC | $11,036,000 | +13.3% | 446,641 | 0.0% | 2.29% | -37.7% | |
| STOK | New | STOKE THERAPEUTICS INC | $9,991,000 | – | 296,822 | +100.0% | 2.07% | – |
| AMAM | New | AMBRX BIOPHARMA INCsponsored ads | $8,820,000 | – | 450,000 | +100.0% | 1.83% | – |
| PMVP | PMV PHARMACEUTICALS INC | $8,540,000 | +3.9% | 250,000 | 0.0% | 1.77% | -42.9% | |
| CNTB | CONNECT BIOPHARMA HLDGS LTDads | $7,294,000 | +5.6% | 373,492 | 0.0% | 1.51% | -42.0% | |
| TSHA | TAYSHA GENE THERAPIES INC | $6,793,000 | +4.4% | 320,440 | 0.0% | 1.41% | -42.6% | |
| CRDF | Buy | CARDIFF ONCOLOGY INC | $6,535,000 | +8.6% | 982,753 | +51.2% | 1.35% | -40.3% |
| IKNA | IKENA ONCOLOGY INC | $5,616,000 | -50.3% | 400,000 | 0.0% | 1.16% | -72.7% | |
| GLUE | New | MONTE ROSA THERAPEUTICS INC | $5,404,000 | – | 238,045 | +100.0% | 1.12% | – |
| DSGN | DESIGN THERAPEUTICS INC | $4,973,000 | -33.5% | 250,000 | 0.0% | 1.03% | -63.4% | |
| RXDX | PROMETHEUS BIOSCIENCES INC | $4,912,000 | +34.5% | 200,000 | 0.0% | 1.02% | -26.1% | |
| KYMR | New | KYMERA THERAPEUTICS INC | $4,850,000 | – | 100,000 | +100.0% | 1.00% | – |
| MRUS | Buy | MERUS N V | $4,360,000 | +4.4% | 206,927 | +3.5% | 0.90% | -42.6% |
| ISEE | IVERIC BIO INC | $4,291,000 | +2.1% | 680,036 | 0.0% | 0.89% | -43.8% | |
| HLXA | HELIX ACQUISITION CORP | $4,132,000 | +1.3% | 400,000 | 0.0% | 0.86% | -44.3% | |
| RVMD | REVOLUTION MEDICINES INC | $4,004,000 | -30.8% | 126,136 | 0.0% | 0.83% | -62.0% | |
| NGM | NGM BIOPHARMACEUTICALS INC | $3,944,000 | -32.2% | 200,000 | 0.0% | 0.82% | -62.7% | |
| KRON | KRONOS BIO INC | $3,501,000 | -18.2% | 146,173 | 0.0% | 0.72% | -55.0% | |
| JYAC | JIYA ACQUISITION CORP | $2,982,000 | +1.0% | 300,000 | 0.0% | 0.62% | -44.4% | |
| EWTX | EDGEWISE THERAPEUTICS INC | $2,666,000 | -34.4% | 125,000 | 0.0% | 0.55% | -63.9% | |
| FHTX | Exit | FOGHORN THERAPEUTICS INC | $0 | – | -69,132 | -100.0% | -0.34% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -150,076 | -100.0% | -2.90% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.